Henry Schein, Inc. (HSIC)
| Market Cap | 9.40B +19.9% |
| Revenue (ttm) | 13.73B +6.2% |
| Net Income | 421.00M +7.7% |
| EPS | 3.65 +15.2% |
| Shares Out | 110.54M |
| PE Ratio | 23.30 |
| Forward PE | 14.67 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 839,914 |
| Open | 89.68 |
| Previous Close | 88.24 |
| Day's Range | 84.78 - 89.68 |
| 52-Week Range | 68.70 - 92.18 |
| Beta | 0.86 |
| Analysts | Buy |
| Price Target | 96.93 (+14.01%) |
| Earnings Date | Nov 3, 2026 |
About HSIC
Henry Schein, Inc. provides health care products and services to office-based dental and medical practitioners worldwide. It operates through Global Distribution and Value-Added Services; Global Specialty Products; and Global Technology segments. The Global Distribution and Value-Added Services segment distributes infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, gypsum, acrylics, articulators, abrasives, PPE products, branded and generic pharmaceuticals, vaccines, surgical products, di... [Read more]
Financial Performance
In 2025, Henry Schein's revenue was $13.18 billion, an increase of 4.03% compared to the previous year's $12.67 billion. Earnings were $398.00 million, an increase of 2.05%.
Financial StatementsAnalyst Summary
According to 16 analysts, the average rating for HSIC stock is "Buy." The 12-month stock price target is $96.93, which is an increase of 14.01% from the latest price.
News
Henry Schein to Participate in Upcoming Investor Conferences in November and December
MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein, Inc. (Nasdaq: HSIC), the world's largest provider of healthcare solutions to office-based dental and medical practitioners, announced today that the Comp...
Henry Schein price target raised to $95 from $94 at UBS
UBS analyst Kevin Caliendo raised the firm’s price target on Henry Schein (HSIC) to $95 from $94 and keeps a Neutral rating on the shares.
Henry Schein Earnings Call Transcript: Q3 2026
Q3 sales grew 4.0%, while underlying adjusted EPS rose 19.1% and non-GAAP operating margin expanded 20 bps. FY2026 EPS guidance increased; management reiterated its value-creation targets and expects double-digit earnings growth in 2027.
Henry Schein Earnings release: Q3 2026
Henry Schein released its Q3 2026 earnings on November 3, 2026, summarizing the period's financial results.
Henry Schein Slides: Q3 2026
Henry Schein has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 3, 2026.
Henry Schein Quarterly report: Q3 2026
Henry Schein has published its Q3 2026 quarterly earnings report on November 3, 2026.
Henry Schein Slides: Corporate presentation
Henry Schein has posted slides in relation to its latest quarterly earnings report, which was published on November 3, 2026.
Henry Schein raises FY26 adjusted EPS view to $5.50-$5.56 from $5.29-$5.39
FY26 consensus $5.39. Backs FY26 revenue growth view 4.5%-5.5%, consensus $13.86B. Raises FY26 adjusted EBITDA growth view to high-single-digits from mid to high single digits.
Henry Schein reports Q3 adjusted EPS $1.56, consensus $1.36
Reports Q3 revenue $3.47B, consensus $3.48B. “We delivered another strong quarter that increases our confidence in the momentum we are building at Henry Schein (HSIC). I am very pleased with…
Henry Schein Reports Strong 2026 Third Quarter and Raises FY2026 Guidance
MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein, Inc. (Nasdaq: HSIC), the world's largest provider of healthcare solutions to office-based dental and medical practitioners, today reported financial resu...
Henry Schein to Webcast Third Quarter 2026 Conference Call on Tuesday, November 3, 2026, at 8:00 a.m. ET
MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein, Inc. (Nasdaq: HSIC), the world's largest provider of healthcare solutions to office-based dental and medical practitioners, announced today that it will ...
Henry Schein price target lowered to $92 from $96 at Leerink
Leerink lowered the firm’s price target on Henry Schein (HSIC) to $92 from $96 and keeps a Market Perform rating on the shares. The firm says there are very few…
Henry Schein appoints Caprais as Chief Financial Officer
Henry Schein (HSIC) announced that Emmanuel Caprais, former Senior Vice President and Chief Financial Officer of ITT, (ITT), has been named the Company’s Senior Vice President and Chief Financial Offi...
Henry Schein Announces Chief Financial Officer Leadership Transition
MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein, Inc. (Nasdaq: HSIC) announced today that Emmanuel Caprais, former Senior Vice President and Chief Financial Officer of ITT, Inc. (NYSE: ITT), has been na...
Henry Schein Cares Marks 25 Years of Helping Health Happen®
MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein Cares, Henry Schein, Inc.'s global corporate citizenship program, is celebrating a quarter century of bringing together Team Schein Members, customers, su...
Henry Schein Transcript: 2026 Global Healthcare Conference
Leadership outlined priorities of accelerating growth, simplifying operations, and increasing rigor, with a $200 million operating income improvement plan and double-digit EPS growth targeted. Dental and medical segments are growing, with strong performance in consumables, private label, and technology. Capital allocation favors disciplined M&A and share buybacks.
Henry Schein, Applied BioCode enter distribution agreement
Applied BioCode announced a distribution agreement with Henry Schein (HSIC) to expand the availability of its BioCode MDx-3000 System and comprehensive molecular diagnostics menu. The BioCode MDx-3000...
Applied BioCode Announces Distribution Agreement with Henry Schein
SANTA FE SPRINGS, Calif.--(BUSINESS WIRE)-- #ClinicalDiagnostics--Applied BioCode today announced a distribution agreement with Henry Schein, a leading provider of healthcare products and services, to...
Henry Schein to Participate in Upcoming Investor Conference in September
MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein, Inc., the world's largest provider of healthcare solutions to office-based dental and medical practitioners, announced today that the Company will presen...
Henry Schein price target raised to $110 from $100 at BTIG
BTIG analyst David Larsen raised the firm’s price target on Henry Schein (HSIC) to $110 from $100 and keeps a Buy rating on the shares as part of a broader…
Henry Schein price target raised to $100 from $86 at Barclays
Barclays raised the firm’s price target on Henry Schein (HSIC) to $100 from $86 and keeps an Overweight rating on the shares. The firm upped estimates citing the company’s “strong”…
Henry Schein price target raised to $104 from $97 at Barrington
Barrington analyst Michael Petusky raised the firm’s price target on Henry Schein (HSIC) to $104 from $97 and keeps an Outperform rating on the shares. The company’s Q2 beat included…
Henry Schein price target raised to $109 from $97 at Baird
Baird analyst Jeff Johnson raised the firm’s price target on Henry Schein (HSIC) to $109 from $97 and keeps an Outperform rating on the shares. The firm updated its model…
Henry Schein price target raised to $86 from $82 at Mizuho
Mizuho analyst Steven Valiquette raised the firm’s price target on Henry Schein (HSIC) to $86 from $82 and keeps a Neutral rating on the shares.
Henry Schein price target raised to $94 from $89 at UBS
UBS analyst Kevin Caliendo raised the firm’s price target on Henry Schein (HSIC) to $94 from $89 and keeps a Neutral rating on the shares. Henry Schein delivered a solid…